Young bone marrow transplantation preserves learning and memory in old mice

Melanie M. Das\textsuperscript{1,2}, Marlesa Godoy\textsuperscript{1,2}, Shuang Chen\textsuperscript{2,3}, V. Alexandra Moser\textsuperscript{1,2}, Pablo Avalos\textsuperscript{1,2}, Kristina M. Roxas\textsuperscript{1,2}, Ivy Dang\textsuperscript{1,2}, Alberto Yáñez\textsuperscript{1,2}, Wenxuan Zhang\textsuperscript{2,3}, Catherine Bresee\textsuperscript{4}, Moshe Arditi\textsuperscript{2,3}, George Y. Liu\textsuperscript{2,3}, Clive N. Svendsen\textsuperscript{1,2} & Helen S. Goodridge\textsuperscript{1,2}

Restoration of cognitive function in old mice by transfer of blood or plasma from young mice has been attributed to reduced C–C motif chemokine ligand 11 (CCL11) and \(\beta\)2-microglobulin, which are thought to suppress neurogenesis in the aging brain. However, the specific role of the hematopoietic system in this rejuvenation has not been defined and the importance of neurogenesis in old mice is unclear. Here we report that transplantation of young bone marrow to rejuvenate the hematopoietic system preserved cognitive function in old recipient mice, despite irradiation-induced suppression of neurogenesis, and without reducing \(\beta\)2-microglobulin. Instead, young bone marrow transplantation preserved synaptic connections and reduced microglial activation in the hippocampus. Circulating CCL11 levels were lower in young bone marrow recipients, and CCL11 administration in young mice had the opposite effect, reducing synapses and increasing microglial activation. In conclusion, young blood or bone marrow may represent a future therapeutic strategy for neurodegenerative disease.
Surgically attaching old mice to young mice so that they share a circulatory system (heterochronic parabiosis) has been reported to rejuvenate old mice and accelerate aging in young mice (reviewed in refs. 1,2). Rejuvenation of the brain, heart, liver and pancreas of old parabionts by young blood is thought to be partly due to effects on stem cell populations (reviewed in refs. 1,2). In particular, improved cognitive function has been attributed to increased neurogenesis3,4 and synaptic plasticity5, as well as better brain vascularization3 and myelination6. A single blood exchange between old and young mice, which replaces the blood without organ sharing or complications associated with the parabiosis procedure, has also recently been reported to have similar effects7.

The blood contains multiple components that influence tissue/organ function and could therefore be responsible for aging/rejuvenation in parabiotic mice, including hematopoietic cells, as well as soluble factors. Plasma transfer experiments have suggested that changes in soluble factors in the circulation are responsible for brain rejuvenation in old mice joined to young mice5,8. Soluble factors of both non-hematopoietic and hematopoietic origin likely contribute to the observed effects. For instance, restoration of the regenerative potential of skeletal muscle in old mice joined to young mice has been attributed to elevated testosterone levels9. Changes in circulating levels of inflammatory cytokines and chemokines may also underlie some of the observed aging/rejuvenation effects of parabiosis. In particular, several chemokines have been reported to be elevated in the circulation of old mice and in young mice joined to old mice3.

Circulating levels of the C–C motif chemokine ligand 11 (CCL11, also known as eotaxin-1) and β2-microglobulin have previously been reported to increase with age in mice and humans, and shown to promote brain aging when administered (CCL11, also known as eotaxin-1) and β2-microglobulin have previously been reported to increase with age in mice and humans, and shown to promote brain aging when administered to young mice3,10,11. Both CCL11 and β2-microglobulin can be produced by a diverse range of cell types, and the tissue(s)/organ(s) responsible for their elevated levels during aging have not been defined. Thus, the role of the hematopoietic system in these effects is unclear.

CCL11 and β2-microglobulin are thought to act by suppressing neurogenesis in the hippocampus, because neurogenesis was enhanced in old mice rejuvenated by parabiosis or plasma transfer, and injection of CCL11 or β2-microglobulin into young mice suppressed neurogenesis3,5,10. However, neurogenesis in the rejuvenated old mice was only partially restored compared to young mice, and the role of neurogenesis in the adult brain is controversial, with some studies suggesting that it is of minimal importance for maintenance of hippocampal function12,13. Thus other mechanisms may be responsible for the rejuvenated cognitive function in old mice undergoing heterochronic parabiosis or plasma transfer. Indeed, while stem cell populations in the neurogenic niche have been closely examined, it is not known whether aging-associated changes in glial cells are also reversed.

We therefore established a heterochronic bone marrow transplant (BMT) model to determine the specific influence of systemic hematopoietic aging on cognitive function, including glial cells in the hippocampus. This approach also allowed us to evaluate the long-term beneficial impact of a young hematopoietic system on the aging brain, and define the role of the hematopoietic system in aging-associated elevation of circulating levels of CCL11 and β2-microglobulin. Irradiation (9 Gy, split dose) delivered without head shielding prior to injection of donor bone marrow cells enabled us to exclude the impact of neurogenesis, because irradiation is known to inhibit the proliferation of neural progenitors15,16.

We found that reconstitution of old mice with young, but not old, hematopoietic cells prevented cognitive decline. BMT achieved preservation of cognitive function for at least 6 months, despite suppression of neurogenesis. Instead, microglial activation was reduced, and synaptic connections were maintained. Our data also attribute the aging-associated elevation of circulating β2-microglobulin levels to non-hematopoietic cells. In contrast, the increased CCL11 appears either to be of hematopoietic origin or to be produced by non-hematopoietic cells under hematopoietic control, and our data implicate CCL11 in aging-associated microglial activation and synaptic loss.

Results

Impact of heterochronic BMT on cognitive function. To evaluate the impact of hematopoietic age on cognitive function, we established a model of heterochronic BMT (Fig. 1a). Old (18-month) recipient mice were irradiated (without head-shielding) prior to injection of donor bone marrow cells from either young (4-month) or old (18-month) mice to achieve nearly complete (>90%) reconstitution with donor bone marrow (Supplementary Fig. 1a). Lymphocyte counts were initially slightly lower in old bone marrow recipients than young bone marrow recipients, but similar by 3 months post-transplantation (Supplementary Fig. 1b).

Behavioral testing was performed 6 months post-transplantation to assess activity and cognition (Fig. 1a). In an open field test, old control mice exploring a novel environment were less active than young control mice during the first 20 min of evaluation (Fig. 1b–c). Remarkably, however, young bone marrow recipients, but not old bone marrow recipients, were more active than old control mice (Fig. 1b–c). At the end of a 1-h assessment period, however, both transplanted groups and old control mice were similarly active (Supplementary Fig. 2a–c), suggesting that general wellness does not underlie the differences in exploratory behavior observed during the first 20 min of testing.

Exploratory behavior is thought to originate in the hippocampus17. We therefore evaluated hippocampus-dependent learning and memory. In the spontaneous alternation maze (Y-maze), old control mice performed worse than young control mice, but young bone marrow recipients completed more spontaneous alternations between the arms of the maze than both old bone marrow recipients and old control mice (Fig. 2a). This suggests that young BMT preserves spatial and working memory in old mice. The old control mice made fewer total arm entries than the young control mice, and transplantation with neither young nor old bone marrow reversed this (Supplementary Fig. 2d).

A context-specific fear conditioning test was next used to evaluate hippocampus-dependent memory. When placed in the same environment in which they had previously received an electric shock, old control mice froze for shorter periods than young control mice (consistent with impaired memory), while young (but not old) bone marrow recipients froze for longer periods than old control mice (Fig. 2b). In contrast, a cue-specific fear conditioning test that assesses amygdala-dependent memory revealed no difference between any of the groups when mice were re-exposed to an audible cue that had preceded the electric shock (Fig. 2e). Collectively, these results confirm that a young hematopoietic system slows the aging-associated decline in hippocampal function.

Learning, spatial memory and memory recall were next assessed using a Barnes maze18. In comparison with old control mice and old bone marrow recipients, young control mice and young bone marrow recipients made only slightly fewer errors when locating an escape hole during the training phase (days 1–4; Fig. 2d). Following a 2-day break, however, young control mice and young bone marrow recipients made fewer errors than old control mice and old bone marrow recipients (day 7; Fig. 2e). The
Behavioral testing, and the mean activity, distance and speed were calculated for each mouse. Assessment over an 8-min period. Locomotion and vertical rearing), distance covered (n = 10–15 mice per group. Box and whisker plots show median, 25th and 75th percentile, maximum and minimum values. ***p < 0.001 (ANOVA with Tukey-Kramer post-hoc test).

Fig. 1 Transplantation with young bone marrow preserved activity in old mice. a Timeline of bone marrow transplantation (BMT), hematopoietic reconstitution (0–3 months post-transplantation), behavioral analysis and tissue harvest for histology and molecular analyses (6 months post-transplantation). Old (18-month) mice received bone marrow from either young (4-month) or old (18-month) donors, and cognitive function was evaluated 6 months later. Non-transplanted old (24-month) and young (4-month) control mice were also evaluated. b-e Activity (b, c, includes horizontal locomotion and vertical rearing), distance covered (d), and speed (e) were assessed during four 5-min intervals over a 20-min period in an open field test, and the mean activity, distance and speed were calculated for each mouse. n = 32–51 mice per group, pooled from 3 independent experiments. Justification for pooling was confirmed by multi-ANOVA analysis. Similarly statistically significant differences were observed in all independent experiments. Box and whisker plots show median, 25th and 75th percentile, maximum and minimum values. **p < 0.01, ***p < 0.001 (ANOVA with Tukey-Kramer post-hoc test).

Fig. 2 Transplantation with young bone marrow prevented cognitive decline in old mice. a Spontaneous alternation between the arms of a Y-maze was assessed over an 8-min period. n = 44–46 mice per group, pooled from 3 independent experiments. Justification for pooling was confirmed by multi-ANOVA analysis. Similarly statistically significant differences or trends towards significance were observed in all independent experiments. b-c Memory of a prior electric shock was evaluated upon re-exposure to the same environment (context-dependent fear conditioning; b) or a tone that had preceded the shock (cue-dependent fear conditioning; c) by assessing freezing during a 5-min re-exposure period. n = 11 mice per group. d-f In a Barnes Maze test, the ability of mice to discover and then recall the location of an escape hole was evaluated during the learning phase (days 1–4; d), after a 2-day break (day 7; e), and following re-positioning of the escape hole (days 8–9; f). The number of errors made prior to successful location of the escape hole was recorded. n = 10–15 mice per group. Box and whisker plots show median, 25th and 75th percentile, maximum and minimum values. *p < 0.05, **p < 0.01, ***p < 0.001 (ANOVA with Tukey-Kramer post-hoc test).

Position of the escape hole was then changed and the number of errors made when discovering the new location was similar across all groups (day 8; Fig. 2f). However, the following day, young control mice and young bone marrow recipients made fewer errors compared to old control mice and old bone marrow recipients (day 9; Fig. 2f). In contrast, the time taken to successfully complete the test was similar across all groups on each day of testing (Supplementary Fig. 2c). Collectively, these data demonstrate that a young hematopoietic system preserves recall ability in old mice.

Impact of heterochronic BMT on neurons and glial cells. We next assessed neuron numbers and synapses in the hippocampus 6 months post-transplantation. Neuron numbers were reduced in the CA3 (but not the CA1) region of the hippocampus in old...
control mice (Fig. 3a, b and Supplementary Fig. 3a), consistent with previous studies\textsuperscript{19}. Following young BMT, we observed a trend towards preservation of neuron numbers in the CA3 region, but it was not statistically significant (Fig. 3b). There was also an aging-associated reduction in the number of doublecortin (DCX)\textsuperscript{+} newly-born neurons in the dentate gyrus, and almost complete ablation of these cells in both young and old bone marrow recipients (Fig. 3c and Supplementary Fig. 3b), presumably due to the irradiation administered prior to transplantation\textsuperscript{15,16}. We also assessed 5-bromo-2'-deoxyuridine (BrDU) incorporation in the dentate gyrus of bone marrow recipients at an earlier time point after transplantation (1 month post-transplant, when the mice were 19 months of age). We observed reduced BrDU incorporation in old control mice at this age compared to young control mice, and this was unchanged following transplantation with either old or young bone marrow (Supplementary Fig. 3c–d). Taken together these data indicate that preservation of cognitive function in the BMT model was independent of neurogenesis.

Neuronal loss is normally preceded by synaptic loss in aging and aging-associated diseases\textsuperscript{20}, and synaptic plasticity has been reported to improve in old mice following heterochronic parabiosis\textsuperscript{8}. Thus, we postulated that synaptic connections may be maintained in young bone marrow recipients. Indeed, we observed an aging-associated decrease in co-localized VGlut1 (pre-synaptic) and Homer1 (post-synaptic) puncta in control mice, and preservation of co-localized puncta in recipients of young, but not old, bone marrow (Fig. 3d and Supplementary Fig. 3e). Moreover, Golgi impregnation of hippocampal neurons revealed a greater spine density in young, but not old, bone marrow recipients compared to old controls (Fig. 3e).

The complex factors C1qA and C3 are both over-expressed in the aging hippocampus and have been implicated in aging-associated cognitive decline\textsuperscript{19,21}. C3 deposition on synapses labels them for detection by microglia, thereby inducing synaptic elimination\textsuperscript{19,22,23}, which may be aberrantly over-active during aging\textsuperscript{20}. We therefore assessed complement expression in the hippocampus, and found that C1qa and C3 mRNA levels were lower in young, but not old, bone marrow recipients (Fig. 3f). We also observed reduced C3 deposition on synapses (co-localized Homer1 and C3 puncta; Supplementary Fig. 3f) in young, but not old, bone marrow recipients compared to old control mice (Fig. 3g).

We next evaluated reactive astrocytes and microglia, which have also been shown to contribute to cognitive decline in aging\textsuperscript{23,24}. We found no difference between the groups in the number of reactive glial fibrillary acidic protein (GFAP)\textsuperscript{+} astrocytes in the hippocampus (Fig. 4a and Supplementary Fig. 4a), but higher Gfap mRNA expression in old control mice and old bone marrow recipients compared to young controls (Fig. 4b). In contrast, Gfap mRNA levels in young bone marrow recipients were reduced to levels seen in young control mice (Fig. 4b). We also evaluated astrocyte hypertrophy by assessing the area and perimeter of GFAP\textsuperscript{+} cells, both of which were increased in old control mice (although only the area reached statistical significance; Fig. 4c). However, we did not observe a statistically significant reduction in astrocyte hypertrophy in the young bone marrow recipients, so preserved cognition could not be attributed to normalization of astrocyte morphology.

Microglia in the hippocampus are specifically vulnerable to aging\textsuperscript{25}. While the number of Iba\textsuperscript{1} microglia was similar in all groups (Fig. 4d–f and Supplementary Fig. 4b), their activation state was very different (Fig. 4d, g–m and Supplementary Fig. 4b). Specifically, the microglia of old control mice exhibited a ‘reactive’ morphology\textsuperscript{26}, with larger soma, as well as fewer and shorter processes than those of young control mice (Fig. 4g–j). This phenotype was reversed in recipients of young, but not old, bone marrow (Fig. 4g–j). In addition, quantification of reactive microglia by immunostaining for CD68 and LAMP1 revealed that more Iba\textsuperscript{1} microglia co-stained with these lysosomal markers in old control mice than young control mice (Fig. 4d, k and Supplementary Fig. 4b), and C1q mRNA levels were also elevated (Fig. 4l). This phenotype was also completely reversed in recipients of young, but not old, bone marrow (Fig. 4d, k–m and Supplementary Fig. 4b). Thus, synapse preservation in the young bone marrow recipients may be a consequence of reduced phagocytic engulfment of synapses by microglia.

### Impact of heterochronic BMT on CCL11 and β2-microglobulin.

We next explored the mechanisms underlying the reduced activation of microglia. Previous studies have shown that donor-derived CD11b\textsuperscript{+} cells can be found in the choroid plexus and meninges of recipient mice following BMT, but rarely infiltrate the brain parenchyma in the absence of acute damage\textsuperscript{26}. Similarly, we did not observe donor-derived cells in the brain 3 weeks after transplantation of young GFP-transgenic bone marrow into old mice (Supplementary Fig. 5a), but 3 months post-transplantation, GFP\textsuperscript{+} CD11b\textsuperscript{+} cells were seen in the choroid plexus and meninges (Supplementary Fig. 5a–c). This is consistent with previous reports that choroid plexus and meningeal macrophages are replaced throughout life\textsuperscript{26}. However, donor-derived cells were not observed in the brain parenchyma (Supplementary Fig. 5a, d). Thus it is likely that the preservation of cognitive function is not due to direct effects of young hematopoietic cells in the hippocampus.

We therefore next investigated whether heterochronic BMT impacts the levels of circulating factors previously implicated in brain aging, focusing on β2-microglobulin and CCL11. Levels of β2-microglobulin and CCL11, which have been shown to suppress neurogenesis upon systemic injection into young mice, are elevated in the circulation and cerebrospinal fluid (CSF) of old mice and humans, and also increased in young parabionts following heterochronic parabiosis\textsuperscript{3,10,11}. As expected, we observed higher plasma levels of both β2-microglobulin and CCL11 in old control mice than young control mice (Fig. 5a). Notably, however, plasma levels of CCL11, but not β2-microglobulin, were reduced in recipients of young (but not old) bone marrow (Fig. 5a). This suggests that non-hematopoietic cells are the main source of β2-microglobulin in old mice, while CCL11 is either derived from hematopoietic cells or produced by non-hematopoietic cells under the influence of hematopoietic cells. Moreover, it raises the possibility that reduced CCL11 production may underlie the preservation of cognitive function in old mice following young BMT.

### Effects of CCL11 injection into young mice.

Microglia express higher levels of the CCL11 receptors CCR2, CCR3 and CCR5 than other brain cell types (including neurons and astrocytes)\textsuperscript{27}. We therefore hypothesized that increased CCL11 production might be responsible for activation of microglia and aberrant synaptic pruning in old mice. To investigate this, we administered recombinant CCL11 to young mice via intraperitoneal injection, which achieves a physiologically relevant increase in circulating CCL11 levels\textsuperscript{3}. Consistent with a previous study\textsuperscript{3}, this resulted in reduced numbers of DCX\textsuperscript{+} newly-born neurons (Supplementary Fig. 6a). We also observed a reduction in CA3, but not CA1, region hippocampal neurons (Fig. 5b). The number of synapses (co-localized VGlut1 and Homer1 puncta) also decreased following CCL11 injection (Fig. 5c), as did the average spine density of Golgi-impregnated neurons (Fig. 5d). Moreover, quantification of co-localized Homer1 and C3 puncta showed that systemic CCL11 injection increased C3 deposition on synapses (Fig. 5e).
which indicated that the reduction in synapses may be a consequence of pruning by microglia. Interestingly, astrocyte activation (GFAP+ cell number and Gfap mRNA expression) was unaffected by CCL11 administration (Supplementary Fig. 6b, c), and Iba1+ microglial numbers were unchanged (Supplementary Fig. 6d). In contrast, microglia in the hippocampus were more reactive, with increased CD68 and LAMP1 expression, as well as fewer and shorter processes (Fig. 5f–i and Supplementary Fig. 6e). Thus CCL11 injection reproduced the synaptic loss and microglial reactivity observed in old mice.

Discussion

Previous studies using a similar approach (although with sex mismatched mice and no irradiation) have suggested that heterochronic BMT can extend lifespan28,29. We have now shown that heterochronic BMT preserves cognitive function in old mice for at least 6 months. Our data suggest that replacement of old peripheral hematopoietic cells with young ones specifically improves hippocampal memory, likely by preventing synapse loss. Although anxiety could impact certain behaviors, there is no indication that anxiety affects hippocampal memory. Indeed, a previous study reported that differences in anxiety have a minimal impact on performance in the Barnes maze30, and in our study, the old mouse groups made a similar number of total arm entries in the Y-maze, suggesting no apparent differences in anxiety.

Taken together, our data support an emerging model of aging-associated cognitive decline that is in part due to activation of microglia and synapse loss, perhaps due to overzealous pruning of synapses by microglia19,20,22,31.

Importantly, in contrast to studies of neurodegenerative diseases in which donor-derived monocytes more readily cross the severely compromised blood-brain-barrier to phagocytose debris

Fig. 3 Synapses were preserved in young bone marrow recipients. Neurons and synapses in the hippocampus were evaluated 6 months post-transplantation. a, b Neuron numbers in the CA1 (a) and CA3 (b) regions were assessed by NeuN staining. n = 6–8 mice per group, pooled from 2 independent experiments. c Newly-born neurons were assessed by counting doublecortin (DCX)+ cells. n = 6 mice per group. d Synapses were counted by evaluating co-localization of VGlut1 (pre-synaptic) and Homer1 (post-synaptic). n = 8 mice per group, pooled from 2 independent experiments. e Spine density was visualized and quantified on Golgi-impregnated slices. Scale bar: 2.5 μm. n = 5 mice per group. f Complement expression was assessed by RT-PCR (normalized to Gapdh mRNA). n = 5 mice per group, pooled from 2 independent experiments. g C3 deposition on synapses was evaluated by assessing C3 co-localization with Homer1. n = 8 mice per group, pooled from 2 independent experiments. The dotplots show mean plus standard deviation.

*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (ANOVA with Tukey-Kramer post-hoc test)
and clear β-amyloid plaques in the brain parenchyma (reviewed in refs. 32,33), cognitive preservation in the old but otherwise healthy mice could not be attributed to donor cell infiltration. Instead, consistent with heterochronic plasma transfer studies5,8, it appears that soluble factors in the circulation are responsible. Interestingly, consistent with a previous report3, our analyses suggest that CCL11 is an important mediator of aging-associated cognitive decline. CCL11 levels are elevated in the circulation of old mice and humans3,11, and CCL11 production has also been reported to be elevated in the brains of old mice34.

The reduction in circulating CCL11 levels that we observed in young bone marrow recipients indicates that CCL11 is either derived from hematopoietic cells or produced by non-hematopoietic cells under hematopoietic control. Consistent with the latter hypothesis, increased CCL11 production by choroid plexus epithelial cells has previously been attributed to an aging-associated shift in T cell polarization34. CCL11 has also been reported to be produced by activated astrocytes27. It remains to be seen whether CCL11 produced inside or outside the brain parenchyma has the biggest impact on the hippocampus. Although circulating levels of CCL11 increase with age3 and CCL11 has been shown to be capable of crossing the blood-brain barrier35, it is possible that targeting brain-derived CCL11 production may be sufficient to preserve cognitive function.

In ongoing studies we are investigating whether there is a causal link between increased CCL11 and synaptic pruning by microglia, but we hypothesize that CCL11 promotes cognitive decline by directly targeting microglia (the brain cells expressing the highest levels of its main receptor, CCR327). Moreover, our data suggest that the preservation of cognitive function following heterochronic BMT may be mediated in part by reduced CCL11-mediated microglial activation, which would be expected to restrict synapse loss. The lack of an effect of heterochronic BMT on β2-microglobulin levels suggests that non-hematopoietic cells are the main source of this factor in old mice, and that while β2-microglobulin levels may increase with age and suppress neurogenesis10, reducing β2-microglobulin is not critical for preservation of cognitive function.

We chose to focus on CCL11 and β2-microglobulin because parabiosis studies have implicated these factors in aging-associated cognitive decline3,10. However, other circulating factors, including cytokines/chemokines, are also likely to operate in concert with CCL11. For instance, aging-associated increases in the production of several inflammatory mediators have been reported (‘inflammaging’, reviewed in ref. 36), both in the circulation and in the brain itself, and changes in circulating levels of several other chemokines have been correlated in a comparison of aging and heterochronic parabiosis3. Of particular relevance to the current study, CCL11 production may be a consequence of a
shift in the T cell cytokine balance or elevated TNF-α production.24-26 Hippocampal function may be impacted by signals derived from both myeloid and lymphoid cells in the periphery, and changes in immune cell composition, polarization and function may underlie the observed effects.

In future studies, it will also be interesting to determine whether transplantation of old bone marrow into young mice has detrimental effects on cognitive function i.e., increased glial activation and synapse loss, accompanied by reduced neurogenesis (which is more important in young mice), resulting in premature cognitive decline. Such studies will likely need to be performed with head-shielding to protect neural progenitors from the toxic effects of irradiation. However, our data provide additional support for the current clinical practice of using young donors for BMT in humans39.

Our study also demonstrates that restoration of neurogenesis is not essential for the preservation of cognitive function, and that microglial rejuvenation via peripheral manipulation of the hematopoietic system may be sufficient to maintain or restore hippocampal function. Moreover, our study presents a potential translational approach for treating neurological diseases associated with aging. Weekly transfusions of young plasma are already being evaluated in Alzheimer’s disease patients (The PLASMA Study, ClinicalTrial.gov NCT02256306)40, but heterochronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longer periods. Heterochronic BMT using traditional protocols for chronic bone marrow reconstitution to replace old hematopoietic stem cells with young ones could provide therapeutic benefit for longe...
aging, and perhaps slow the progression of aging-associated diseases such as Alzheimer’s and Parkinson’s disease.

Methods

**Mice, bone marrow transplantation (BMT), and CCL11 injections.** Male wild type (CD45.1 and CD45.2 congenic strains) and green fluorescent protein (GFP)-transgenic mice (all on a C57BL/6 background) were purchased from The Jackson Laboratory (Bar Harbor, ME) and maintained in house. Mice were purchased at 3 months of age or 12 months of age and aged in house until the appropriate age for experiments. All procedures were approved by Cedars-Sinai Medical Center’s Institutional Animal Care and Use Committee.

Recipient 8-month-old (CD45.2) and donor 18-month-old (CD45.1) mice were irradiated (9 Gy split dose from a gamma source i.e., two 4.5 Gy doses, 2 h apart, without head-shielding), and 4 h later received 2 million young (4-month; CD45.1 and CD45.2) or old (18-month; CD45.2, or CD45.1 if indicated) donor bone marrow cells (pooled from the femurs and tibias of donor mice) by intravenous injection. Irradiation without head shielding prior to injection of donor bone marrow cells enabled us to exclude the impact of neurogenesis, because irradiation is known to inhibit the proliferation of neural progenitors. For BrdU analysis, mice received 3 intraperitoneal injections of 4 mg 5-bromo-2′-deoxyuridine (BrdU) daily on 5 consecutive days and were euthanized 2 h after the final injection. For CCL11 injections, mice received 4 intraperitoneal injections of recombinant mouse CCL11 (10 μg per kg; R&D Systems, Minneapolis, MN) over the course of 10 days, consistent with a previously published protocol.

**Behavioral testing.** Behavioral testing was performed in a blinded manner, 6 months post-transplantation.

Open field testing: Mice were placed in an open-topped, clear Plexiglass chamber (left undisturbed for 60 min. Activity (number of crossings horizontal projection and vertical rearing), speed and distance were tracked by disturbances in a grid of photoembs in the chamber, which were recorded using tracking software (Noldus, Leesburg, VA) and analyzed at 5-min intervals.

Spontaneous alternation (Y-maze) testing: Mice were placed in an opaque, Y-shaped maze (San Diego Instruments, San Diego, CA) and spontaneous alternation of the mice between the three arms of the maze was recorded for 8 min.

Context- and cue-dependent fear conditioning: Fear-conditioning tests were performed as described previously. Mice were placed in a chamber where they received a loud tone paired with a mild (0.3 mA) electric shock. To assess context-dependent fear, mice were placed in the same chamber the following day and freezing (indicative of fear of another shock) was recorded for 5 min. The following day, cue-dependent fear conditioning was assessed by placing the mice in a novel chamber where the tone was re-played and freezing was recorded for 5 min. Freezing was measured using the Freeze Monitor tracking system and software (San Diego Instruments, San Diego, CA) and is presented as the proportion of the evaluation period that mice exhibited freezing.

Barnes maze: Barnes maze testing was performed as described previously. Briefly, mice were placed under a bright light on a circular platform with 20 holes around the perimeter, one of which provided access to a small dark chamber (escape box). Colored shapes were placed around the maze to serve as visual cues. Mice were trained to find the escape box 3 times per day for 4 days (training phase, days 1–4). After a 2-day break, mice were tested on the maze (day 7) and the number of errors and time to find the escape box were recorded. The following day, the escape box was moved to the opposite side of the maze (reversal phase) and the mice were tested again on 2 consecutive days (days 8–9).

**Histological analyses.** Samples for histological analysis were randomly selected from independent experiments and pooled for analysis to control for potential differences between experiments. Histological assessments were performed in a blinded manner. Hemibrains were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) for 24 h and cryoprotected in 30% sucrose for 48 h. 0.3 μm coronal or sagittal sections were cut on a Leica SM2010R freezing microtome and stored in Schematized Medium (30% Sucrose + 30% Ethylene Glycol in 0.1 M Phosphate Buffer) at 4 °C until used for blinded manner. Hemibrains were from independent experiments and pooled for analysis to control for potential differences between experiments. Samples from each mouse were assessed in duplicate. RNA was extracted from fast-frozen hippocampi using TRIzol (Thermo-Fisher Scientific, Waltham, MA) and an RNeasy Kit (Qiagen, Valencia, CA), and then digested using DNAse I (RQ1 DNAse, Promega, Madison, WI) according to the manufacturer’s protocol. Complementary DNA was generated from 0.5 μg total RNA using a reverse transcriptase kit (Thermo-Fischer Scientific, Waltham, MA) on a C1000 Thermal Cycler. Quantitative PCR analyses were run on a CFX384 Real-Time Thermal Cycler. Quantitative PCR analysis samples were randomly selected from independent experiments and pooled for analysis to control for potential differences between experiments. Samples from each mouse were assessed in duplicate. RNA was extracted from fast-frozen hippocampi using TRIzol (Thermo-Fisher Scientific, Waltham, MA) and an RNeasy Kit (Qiagen, Valencia, CA), and then digested using DNAse I (RQ1 DNAse, Promega, Madison, WI) according to the manufacturer’s protocol. Complementary DNA was generated from 0.5 μg total RNA using a reverse transcriptase kit (Thermo-Fischer Scientific, Waltham, MA) on a C1000 Thermal Cycler. Quantitative PCR analysis were run on a CFX384 Real-Time Thermal Cycler.
1. Hoefler, J. et al. The ‘Aging Factor’ Eotaxin-1 (CCL11) Is Detectable in Transfusion Blood Products and Increases with the Donor’s Age. Front. Aging Neurosci. 9, 402 (2017).
2. Groves, J. O. et al. Ablating adult neurogenesis in the rat has no effect on spatial processing: evidence from a novel pharmacogenetic model. PLoS Genet. 9, e1003718 (2013).
3. Ko, H. G. et al. Effect of ablated hippocampal neurogenesis on the formation of contextual extinction: a neurochemical analysis. Front. Behav. Neurosci. 2, 1 (2009).
4. Shors, T. J., Townsend, D. A., Zhao, M., Kozorovitskiy, Y. & Gould, E. Neurogenesis may relate to some but not all types of hippocampal-dependent learning. Hippocampus 12, 578–584 (2002).
5. Monje, M. L., Toda, H. & Palmer, T. D. Inflammatory blockade restores adult hippocampal neurogenesis. Science 302, 1760–1765 (2003).
6. Monje, M. L., Muzman, S., Fike, J. R. & Palmer, T. D. Irradiation induces neural precursor-cell dysfunction. Nat. Med. 8, 955–962 (2002).
7. Voss, J. L., Gonsalves, B. D., Federman, K. D., Tranell, D. & Cohen, N. J. Hippocampal brain-network coordination during volitional exploratory behavior enhances learning. Nat. Neurosci. 14, 115–120 (2011).
8. Barnes, C. A. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol. 93, 74–104 (1979).
9. Shi, Q. et al. Complement C3-deficient mice fail to display age-related hippocampal decline. J. Neurosci. 35, 13029–13042 (2015).
10. Morrison, J. H. & Baxter, M. G. The ageing cortical synapse: hallmarks and implications for cognitive decline. Nat. Rev. Neurosci. 13, 240–250 (2012).
11. Stephan, A. H. et al. A dramatic increase of C1q protein in the CNS with normal aging. J. Neurosci. 33, 13460–13474 (2013).
12. Stevens, B. et al. The classical complement cascade mediates CNS synaptic elimination. Cell 131, 1164–1178 (2007).
13. Schaf, D. P. et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 74, 691–705 (2012).
14. Rodríguez-Arellano, J. I., Parpura, V., Zorc, R. & Verkhratsky, A. Astrocytes in physiological aging and Alzheimer’s disease. Neuroscience 323, 170–182 (2016).
15. Grabert, K. et al. Microglial brain region-dependent diversity and selective regional sensitivities to aging. Nat. Neurosci. 19, 504–516 (2016).
16. Goldmann, T. et al. Origin, fate and dynamics of macrophages at central nervous system interfaces. Nat. Immunol. 17, 797–805 (2016).
17. Parajuli, B., Horiuichi, H., Mizuno, T., Takeuchi, H. & Suzumura, A. CCL11 enhances excitotoxic neuronal death by producing reactive oxygen species in microglia. Glia 63, 2274–2284 (2015).
18. Kammenga, L. M. et al. Impaired hematopoietic stem cell functioning after serial transplantation and during normal aging. Stem Cells 23, 82–92 (2005).
19. Kovina, M. V., Zuev, V. A., Kagarlitisky, G. O. & Khodorovich, Y. M. Effect on lifespan of high yield non-myoeloblastic transplantation of bone marrow from young to old mice. Front. Genet. 4, 144 (2013).
20. Harrison, P. E., Hosseini, A. H. & McDonald, M. P. Endogenous anxiety and stress responses in water maze and Barnes maze spatial memory tasks. Behav. Brain Res. 198, 247–251 (2009).
21. Fan, X., Wheatley, E. G. & Villeda, S. A. Mechanisms of Hippocampal Aging and the Potential for Rejuvenation. Annu. Rev. Neurosci. 40, 251–272 (2017).
22. Prinz, M., Priller, J., Sisodia, S. S. & Ransohoff, R. M. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 14, 1227–1235 (2011).
23. Theriault, P., ElAli, A. & Rivest, S. The dynamics of monocytes and microglia in Alzheimer’s disease. Alzheimers Res. Ther. 7, 41 (2015).
24. Baruch, K. et al. CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc. Natl Acad. Sci. USA 110, 2504–2509 (2013).
25. Erickson, M. A., Moroofii, Y., Owen, J. B. & Banks, W. A. Rapid transport of CCL11 across the blood-brain barrier: regional variation and importance of blood cells. J. Pharmacol. Exp. Ther. 349, 497–507 (2014).
26. Franceschi, C., Garagnani, P., Vitale, G., Capri, M. & Salvioni, S. Inflammaging and ‘Garb-aging’. Trends Endocrinol. Metab. 28, 199–212 (2017).
27. Lilly, C. M. et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. J. Clin. Invest. 99, 1767–1773 (1997).
28. Stellato, C. et al. Differential regulation of epithelial-derived C-C chemokine expression by IL-4 and the glucocorticoid budesonide. J. Immunol. 163, 5624–5632 (1999).
29. Kollman, C. et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 98, 2043–2051 (2001).
30. Sha, S. J. et al. Safety, tolerability, and feasibility of young plasma infusion in the plasma for Alzheimer Symptoms Amelioration Study: a randomized clinical trial. JAMA Neurol. 76, 35–40 (2019).
41. Sugimura, R. et al. Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature 545, 432–438 (2017).
42. Risher, W. C., Ustunkaya, T.; Singh Alvarado, J. & Eroglu, C. Rapid Golgi analysis method for efficient and unbiased classification of dendritic spines. PLoS ONE 9, e107591 (2014).

Acknowledgements
This work was supported by the Cedars-Sinai Board of Governor’s Regenerative Medicine Institute. We would like to express our gratitude to Dr. Soshana Svendsen for her critical review and editing of the manuscript. We would also like to acknowledge Patrick Suezaki and Drs. Andrew J. Brumm, Nargess Hassanzadeh-Kiabi, Jean-Philipe Vit, Miklos Peterfy and Nicole Ehrhardt for technical assistance and helpful discussions.

Author contributions
M.M.D., S.C., G.Y.L., M.A., C.N.S. and H.S.G. designed the study; M.M.D., M.G., S.C., V.A.M., P.A., K.M.R., I.D., A.Y., W.Z., G.Y.L. and H.S.G. performed experiments; M.M.D., V.A.M., C.B., C.N.S. and H.S.G. analyzed the data; M.M.D., C.N.S. and H.S.G. wrote the manuscript.

Additional information
Supplementary information accompanies this paper at https://doi.org/10.1038/s42003-019-0298-5.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2019